Abiomed
在场
是其中之一......
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson 是一家在股票代码 JNJ (US) 下上市的公司。
Johnson & Johnson 在 23 个国家有直接业务。Johnson & Johnson 拥有 65家子公司，其中包括 Abiomed、Ambrx 和 DePuy Synthes。
他们在：
涉及Johnson & Johnson的并购和融资。
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024六月21号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024五月20号).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (公布2024四月6号).
- Johnson & Johnson 已收购 Ambrx (公布2024一月11号).
- 查看更多"Johnson & Johnson"相关新闻 Hide news involving Johnson & Johnson
高管
查看带有其 13 名主要高管的组织结构图
Abiomed 搜索最多的简介
- Andrew Greenfield, President
- Nonna Akopyan, Head of Legal
- Thorsten Siess, Executive Vice President, Managing Director and Ch...
高管在Johnson & Johnson变化
- Scott Davis, Director, 正在办理退休 (新闻发布的2024九月11号).
- Kristen Mulholland 曾任 Head of Human Resources, Global Total Rewards, 将于 202410月1 升职为 Chief Human Resources Officer (新闻发布的2024八月26号).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, 将于 202410月1 退休 (新闻发布的2024八月26号).
创建提醒
跟踪 Abiomed 的高管变动
医疗设备
Johnson & Johnson 拥有 1,000 家竞争者，其中包括 Philips (荷兰)、Medtronic (爱尔兰岛) 和 Thermo Fisher Scientific (美国(美洲))。
Popular M&A news in 医疗设备
- Vitara Biomedical 刚刚宣布为 50 筹款数百万美元。 (公布2024十一月27号).
- Boston Scientific 已收购 Axonics Modulation Technologies (公布2024十一月18号).
- ShiraTronics 刚刚宣布为 66 筹款数百万美元。 (公布2024十月23号).
医疗设备 行业的其他推荐联系人
消息
Abiomed 的最新新闻稿
- Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
- Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
- Johnson & Johnson MedTech Receives IDE Approval for OTTAVA™ Robotic Surgical System
- Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
- Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
- TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
- New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
- DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
- Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
- View more press releases Close
关于 Abiomed 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Andrew Greenfield 
